{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:11:10Z","timestamp":1782587470987,"version":"3.54.5"},"reference-count":46,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP24K11112"],"award-info":[{"award-number":["JP24K11112"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25fk0210143s0502"],"award-info":[{"award-number":["25fk0210143s0502"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatitis B virus (HBV) particles containing HBV RNA are secreted into the blood; these RNA-containing particles are non-infectious byproducts of the replication cycle and are distinct from mature, DNA-containing virions. The proportion of these particles increases during nucleoside\/nucleotide analog therapy, but the clinical significance of serum HBV RNA remains unclear. We evaluated longitudinal changes in serum HBV RNA and their association with the antiviral efficacy of nucleoside\/nucleotide analog therapy. Eighty-six patients with chronic HBV infection (baseline HBV DNA \u2265 5.0 Log IU\/mL and ALT &lt; 500 U\/L) treated with entecavir (ETV, N = 80) or tenofovir alafenamide (TAF, N = 6) were included. Serum HBV RNA was quantified using Cobas HBV RNA (RUO) at baseline, week 12, and week 48. Associations with clinical variables and treatment response were analyzed. Baseline HBV RNA correlated with HBsAg, HBV DNA, and hepatitis B core-related antigen. Both HBV DNA and RNA tended to decrease with advanced liver fibrosis. HBV DNA and RNA declines did not differ between HBeAg-positive and -negative patients, but the HBV RNA\/DNA ratio at week 48 was significantly higher in HBeAg-positive cases (p &lt; 0.001). Patients with baseline ALT \u2265 100 U\/L showed significantly lower RNA levels at weeks 12 and 48 (p = 0.004, p &lt; 0.001). While HBV DNA decline was similar between ETV and TAF (p = 0.076), RNA decline was significantly greater with TAF at week 12 (p = 0.027). Serum HBV RNA reflects intrahepatic viral replication and may not be influenced by fibrosis progression. HBV RNA decline during nucleoside\/nucleotide analog therapy differed between ETV and TAF, suggesting drug-specific effects on viral RNA dynamics.<\/jats:p>","DOI":"10.3390\/ijms262010141","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:18:54Z","timestamp":1760948334000},"page":"10141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utility of Serum HBV RNA Measurement During Nucleoside\/Nucleotide Analog Therapy in Chronic Hepatitis B Patients"],"prefix":"10.3390","volume":"26","author":[{"given":"Keiichi","family":"Hiraoka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8287","authenticated-orcid":false,"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"},{"name":"Liver Center, Hiroshima University Hospital, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4960","authenticated-orcid":false,"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"},{"name":"Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-945X","authenticated-orcid":false,"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-2795","authenticated-orcid":false,"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-9826","authenticated-orcid":false,"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-3544","authenticated-orcid":false,"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Kashiyama","sequence":"additional","affiliation":[{"name":"Section of Clinical Laboratory, Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-1016","authenticated-orcid":false,"given":"Sho","family":"Mokuda","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Hiroshima University Hospital, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","article-title":"Natural history of chronic hepatitis B: What exactly has REVEAL revealed?","volume":"32","author":"Iloeje","year":"2012","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/scbi.2000.0321","article-title":"Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)","volume":"10","author":"Brechot","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, W., Wang, S., Jin, Y., Mu, X., Guo, Z., Qiao, S., Jiang, S., Liu, Q., and Cui, X. (2024). The role of the hepatitis B virus genome and its integration in the hepatocellular carcinoma. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1469016"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygeno.2021.11.025","article-title":"The integration model of hepatitis B virus genome in hepatocellular carcinoma cells based on high-throughput long-read sequencing","volume":"114","author":"Li","year":"2022","journal-title":"Genomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/gut.2004.054452","article-title":"Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas","volume":"54","author":"Murakami","year":"2005","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(02)00431-2","article-title":"Management of chronic hepatitis B","volume":"38","author":"Conjeevaram","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2009.00633.x","article-title":"Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan","volume":"40","author":"Kumada","year":"2010","journal-title":"Hepatol Res"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","article-title":"Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Magri, A., Harris, J.M., D\u2019Arienzo, V., Minisini, R., Juhling, F., Wing, P.A.C., Rapetti, R., Leutner, M., Testoni, B., and Baumert, T.F. (2022). Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses, 14.","DOI":"10.3390\/v14051070"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0115022","DOI":"10.1128\/jvi.01150-22","article-title":"Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis","volume":"96","author":"Zhao","year":"2022","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acsinfecdis.8b00081","article-title":"Virological Basis for the Cure of Chronic Hepatitis B","volume":"5","author":"Hu","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","author":"Block","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a021386","DOI":"10.1101\/cshperspect.a021386","article-title":"Hepadnavirus Genome Replication and Persistence","volume":"5","author":"Hu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.21581","article-title":"Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine","volume":"45","author":"Hatakeyama","year":"2007","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3851\/IMP1508","article-title":"Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B","volume":"15","author":"Huang","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_18","first-page":"2005","article-title":"Circulating hepatitis B virus nucleic acids in chronic infection: Representation of differently polyadenylated viral transcripts during progression to nonreplicative stages","volume":"7","author":"Su","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jmv.10464","article-title":"Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy","volume":"71","author":"Zhang","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","author":"Tsuge","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00535-025-02211-5","article-title":"Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B","volume":"60","author":"Kosaka","year":"2025","journal-title":"J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","article-title":"Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals","volume":"99\u2013100","author":"Huang","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.3748\/wjg.v27.i43.7497","article-title":"Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases","volume":"27","author":"Kawanaka","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12985-024-02368-0","article-title":"Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase","volume":"21","author":"Wang","year":"2024","journal-title":"Virol. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","article-title":"Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients","volume":"57","author":"Ono","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/hepr.13449","article-title":"Anti-viral effects of interferon-lambda3 on hepatitis B virus infection in cell culture","volume":"50","author":"Yamada","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1478-3231.2005.01200.x","article-title":"Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance","volume":"26","author":"Tanaka","year":"2006","journal-title":"Liver Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(17)31347-8","article-title":"A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): Efficacy and safety results at week 96","volume":"66","author":"Agarwal","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","article-title":"Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B","volume":"17","author":"Gish","year":"2010","journal-title":"J. Viral Hepat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Naive Patients with a Partial Virological Response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ohlendorf, V., Bremer, B., Sandmann, L., Mix, C., Tergast, T., Cornberg, M., Wedemeyer, H., Deterding, K., and Maasoumy, B. (2024). Limited stability of Hepatitis B virus RNA in plasma and serum. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-77329-2"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep4.1520","article-title":"HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination","volume":"4","author":"Maasoumy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cortese, M.F., Riveiro-Barciela, M., Tabernero, D., Rodriguez-Algarra, F., Palom, A., Sopena, S., Rando-Segura, A., Roade, L., Kuchta, A., and Ferrer-Costa, R. (2022). Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: A Promising Marker of Infection Follow-Up. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02149-21"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:43:35Z","timestamp":1761054215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":46,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms262010141"],"URL":"https:\/\/doi.org\/10.3390\/ijms262010141","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]}}}